[1]梁淑影,王 峰,王 珺,等.5-氟尿嘧啶血药浓度对替吉奥联合紫杉醇治疗晚期胃癌疗效的评估价值*[J].郑州大学学报(医学版),2017,(03):339-343.[doi:10.13705/j.issn.1671-6825.2017.03.024]
 LIANG Shuying,WANG Feng,WANG Jun,et al.Value of plasma concentration of 5-fluorouracil in assessing efficacy of S-1 plus paclitaxel in treatment of advanced gastric cancer[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2017,(03):339-343.[doi:10.13705/j.issn.1671-6825.2017.03.024]
点击复制

5-氟尿嘧啶血药浓度对替吉奥联合紫杉醇治疗晚期胃癌疗效的评估价值*()
分享到:

《郑州大学学报(医学版)》[ISSN:1671-6825/CN:41-1340/R]

卷:
期数:
2017年03期
页码:
339-343
栏目:
应用研究
出版日期:
2017-05-15

文章信息/Info

Title:
Value of plasma concentration of 5-fluorouracil in assessing efficacy of S-1 plus paclitaxel in treatment of advanced gastric cancer
作者:
梁淑影王 峰王 珺何 炜樊青霞#
郑州大学第一附属医院肿瘤科 郑州 450052
Author(s):
LIANG Shuying WANG Feng WANG Jun HE Wei FAN Qingxia
Department of Oncology, the First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052
关键词:
晚期胃癌 替吉奥 5-氟尿嘧啶
Keywords:
advanced gastric cancer S-1 5-fluorouracil
分类号:
R735.2
DOI:
10.13705/j.issn.1671-6825.2017.03.024
摘要:
目的:探讨5-氟尿嘧啶(5-FU)血药浓度与替吉奥联合紫杉醇治疗晚期胃癌患者的疗效和安全性之间的关系。方法:选取78例接受替吉奥联合紫杉醇治疗的晚期胃癌患者,于每一个化疗周期监测5-FU血药浓度。分析5-FU血药浓度与疗效和安全性的关系。结果:78例患者不同化疗周期5-FU的中位血药浓度为150 μg/L,据此将患者分为A组(≥150 μg/L,40例)和B组(<150 μg/L,38例)。A组有效率及疾病控制率均高于B组(50.0% vs 18.4%,82.5% vs 65.8%,P均<0.05)。A组骨髓抑制及口腔炎较B组严重(P均<0.05); 但2组间恶心、呕吐及腹泻的严重程度差异无统计学意义(P均>0.05)。结论:5-FU血药浓度≥150 μg/L的晚期胃癌患者采用替吉奥联合紫杉醇治疗有更好的生存获益,但会增加骨髓抑制及口腔炎等不良反应的严重程度。
Abstract:
Aim: To explore the relation between the plasma concentration of 5-fluorouracil(5-FU)and the efficacy and safety of S-1 plus paclitaxel as chemotherapy in patients with advanced gastric cancer.Methods: A total of 78 advanced gastric cancer patients receiving S-1 plus paclitaxel chemotherapy were collected. The plasma concentration of 5-FU was examined at each cycle of chemotherapy. The relation between plasma concentration of 5-FU and the efficacy and safety of the chemotherapy was assessed.Results: The median plasma concentration of 5-FU was 150 μg/L. The patients were allocated into Group A(plasma concentration of 5-FU≥150 μg/L, n=40)and Group B(plasma concentration of 5-FU<150 μg/L, n=38).Significant differences were observed in response rate(50.0% vs 18.4%, P<0.05)and disease control rate(82.5% vs 65.8%, P<0.05). The myelosuppression and mucositis in Group A was more severe than those in Group B(P<0.05). There were no significant differences between Group A and Group B in nausea,vomiting and diarrhea(P>0.05).Conclusion: For advanced gastric cancer patients receiving S-1 and paclitaxel as chemotherapy, those with the plasma concentration of 5-FU≥150 μg/L can obtain better survival benefit, but the severity of myelosuppression and mucositis will increase at the same time.

参考文献/References:

[1] TORRE LA,BRAY F,SIEGEL RL,et al.Global cancer statistics, 2012[J].CA Cancer J Clin,2015,65(2):87
[2] KANG BW,KWON OK,CHUNG HY,et al.Taxanes in the treatment of advanced gastric cancer[J].Molecules,2016,21(5):651
[3] SHITARA K,MATSUO K,MIZOTA A,et al.Association of fluoropyrimidines, platinum agents, taxanes, and irinotecan in any line of chemotherapy with survival in patients with advanced gastric cancer[J].Gastric Cancer,2011,14(2):155
[4] WAGNER AD,GROTHE W,HAERTING J,et al.Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data[J].J Clin Oncol,2006,24(18):2903
[5] AJANI JA.Evolving chemotherapy for advanced gastric cancer[J].Oncologist,2005,10(Suppl 3):49
[6] KOIZUMI W,KURIHARA M,NAKANO S,et al.Phase Ⅱ study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group[J].Oncology,2000,58(3):191
[7] KODERA Y,FUJIWARA M,YOKOYAMA H,et al.Combination of oral fluoropyrimidine and docetaxel: reappraisal of synergistic effect against gastric carcinoma xenografts[J].In Vivo,2005,19(5):861
[8] MOCHIKI E,OGATA K,OHNO T,et al.Phase Ⅱ multi-institutional prospective randomised trial comparing S-1+paclitaxel with S-1+cisplatin in patients with unresectable and/or recurrent advanced gastric cancer[J].Br J Cancer,2012,107(1):31
[9] 刘文静,赵艳秋,胡秀峰,等,紫杉醇脂质体联合替吉奥治疗晚期胃癌的有效性及安全性评价[J].郑州大学学报(医学版),2014,49(6):783
[10]PATEL JN,O'NEIL BH,DEAL AM,et al.A community-based multicenter trial of pharmacokinetically guided 5-fluorouracil dosing for personalized colorectal cancer therapy[J].Oncologist,2014,19(9):959
[11]CHEN XD,HE FQ,CHEN M,et al.Can S-1 replace fluorouracil for advanced gastric cancer? A PRISMA-compliant systematic review and meta-analysis[J].Medicine,2016,95(24):e3916
[12]SHIRASAKA T.Development history and concept of an oral anticancer agent S-1(TS-1): its clinical usefulness and future vistas[J].Jpn J Clin Oncol,2009,39(1):2
[13]彭方慧,王峰,何炜,等.替吉奥与5氟尿嘧啶联合奈达铂治疗晚期食管癌的疗效比较[J].郑州大学学报(医学版),2013,48(2):160
[14]HEGGIE GD,SOMMADOSSI JP,CROSS DS,et al.Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile[J].Cancer Res,1987,47(8):2203
[15]朱仲玲,薛津怀,阎昭,等.肿瘤患者单次和多次口服替吉奥片的药动学研究[J].中国肿瘤临床,2011,38(10):594
[16]KALDATE RR,HAREGEWOIN A,GRIER CE,et al.Modeling the 5-fluorouracil area under the curve versus dose relationship to develop a pharmacokinetic dosing algorithm for colorectal cancer patients receiving FOLFOX6[J].Oncologist,2012,17(3):296
[17]宋卫峰,王雷,蔡讯,等.5-氟尿嘧啶血药浓度预测卡培他滨联合顺铂一线治疗晚期胃癌的疗效和安全性的单中心临床研究[J].肿瘤,2013,33(9):795
[18]LIM HS, RYU KW, LEE JH, et al. Postgastrectomy pharmacokinetic changes of S-1 in patients with localized advanced gastric cancer[J].J Clin Pharmacol,2015,55(8):926
[19]VAN KUILENBURG AB,MARING JG,SCHALHORN A,et al.Pharmacokinetics of 5-fluorouracil in patients heterozygous for the IVS14+1G>A mutation in the dihydropyrimidine dehydrogenase gene[J].Nucleosides Nucleotides Nucleic Acids,2008,27(6):692
[20]CERIC' T, OBRALIC' N, KAPUR-POJSKIC' L, et al. Investigation of IVS14+1G>A polymorphism of DPYD gene in a group of Bosnian patients treated with 5-Fluorouracil and capecitabine[J].Bosn J Basic Med Sci,2010,10(2):133
[21]DOLEGOWSKA B,OSTAPOWICZ A,STANCZYK-DUNAJ M,et al.Spectrophotometric methods as a novel screening approach for analysis of dihydropyrimidine dehydrogenase activity before treatment with 5-fluorouracil chemotherapy[J].J Physiol Pharmacol,2012,63(4):411
[22]LEUNG HW, CHAN AL. Association and prediction of severe 5-fluorouracil toxicity with dihydropyrimidine dehydrogenase gene polymorphisms: A meta-analysis[J].Biomed Rep,2015,3(6):879

相似文献/References:

[1]乔林邦△.人参皂苷Rg3联合XELOX方案治疗晚期胃癌疗效观察[J].郑州大学学报(医学版),2009,(04):844.
 QIAO Linbang.Effect observation of ginsenoside Rg3 combined with XELOX regimen in patients with advanced carcinoma of stomach[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2009,(03):844.
[2]刘文静,赵艳秋,胡秀峰,等.紫杉醇脂质体联合替吉奥治疗晚期胃癌的有效性及安全性评价*[J].郑州大学学报(医学版),2014,(06):783.
 LIU Wenjing,ZHAO Yanqiu,HU Xiufeng,et al.Effectiveness and safety evaluation of paclitaxel liposome combined with S1 in treatment of advanced gastric cancer[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2014,(03):783.

备注/Memo

备注/Memo:
*河南省教育厅科学技术研究重点项目 13A320638
#通信作者,女,1952年6月生,教授,主任医师,研究方向:恶性肿瘤的综合治疗,E-mail:fqx2243@126.com
更新日期/Last Update: 2017-05-20